Description

• Title:
  Eryptosis in polycythemia vera and essential thrombocythemia
• Creator:
  Kopka, Paweł;
  Bliźniewska, Katarzyna;
  Treliński, Jacek;
  Chojnowski, Krzysztof;
  Sicińska, Paulina;
  Duchnowicz, Piotr;
  Bukowska, Bożena
• Contributor:
  Department of Hemostasis Disorders, Medical University of Lodz, Department of Hematology, Copernicus Memorial Hospital, Lodz, Poland;
  Department of Environmental Pollution Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
• Description:
  Aim: Polycythemia vera (PV) and essential thrombocythemia (ET) are Philadelphia–negative myeloproliferative neoplasms with documented apoptosis impairment at the level of hematopoietic stem cell. However, so far no study has evaluated apoptosis of circulating blood neoplastic cells, including the suicidal death of erythrocytes – eryptosis. Material/Methods: Erythrocytes from 61 patients (24 PV and 37 ET) naïve to and treated with hydroxyurea (HU) and 13 healthy individuals were analysed using flow cytometry to quantify phosphatidylserine (PS) externalization from Annexin-V-binding, calpain activity from 7-amino-4-chloromethylcoumarin (CMAC)-fluorescence, cell volume from forward scattered light (FSC) and cell shape from side scattered light (SSC). Results: Significantly increased levels of calpain activity and PS exposure were observed in both ET and PV naïve patients, indicating enhanced eryptosis. Among HU-treated patients, a significant increase in calpain activity in the ET group and a decrease in the PV group were observed compared to patients without cytoreductive therapy. Among PV patients, FSC was substantially higher in the HU-treated group than in the naïve group, whereas no significant differences were found between HU-treated and HU-naïve groups of ET patients. Conclusions: The enhanced eryptosis in ET and PV patients may be a form of systemic compensation of the pathological bone marrow overproduction of erythrocytes. HU, the basic cytoreductive drug used in ET and PV, may affect eryptosis in PV and ET in different ways depending on disease. The JAK2V617F mutation was not observed to have any effect on eryptosis in ET.;
  The study was supported by Medical University of Lodz grant number: 502-03/1-093-02/502-14-347.
• Object availability:
  free access
• Rights:
  Uznanie autorstwa-Użycie niekomercyjne 4.0 Międzynarodowe;
  http://creativecommons.org/licenses/by-nc/4.0
• Date:
  2021.10.15;
  2020
• Type:
  Article
• Language:
  English
• Format:
  application/pdf
• Publisher:
  Sciendo, De Gruyter Poland Sp. z o.o.; Instytut Immunologii i Terapii Doświadczalnej PAN
• Relation:
  Postępy Higieny i Medycyny Doświadczalnej / Advances in Hygiene and Experimental Medicine;74
• Subject:
  Essential thrombocythemia;
  Polycythemia vera;
  Eryptosis;
  Hydroxyurea;
  JAK2V617F mutation
• Identifier:
  0032-5449;
  http://hdl.handle.net/11089/39391 ;
  1732-2693;
  10.5604/01.3001.0014.0855
• Data provider:
  Repozytorium Uniwersytetu Łódzkiego
• Can I use it?:
  seek permission
• Type:
  image